Exosomes have become a major focus in modern biomedical research as scientists attempt to understand the underlying causes of illness, identify novel biomarkers, and develop effective therapeutics.

First human dosing of PlexarisTM has occurred in Exopharm’s PLEXOVAL Study PLEXOVAL is a world-first study using a cell free, platelet-derived exosome product manufactured using Exopharm's proprietary ...

Subject to TSX Venture Exchange (“ TSXV ”) approval, NurExone has engaged Russo Partners LLC, a New York–based strategic communications firm, (“ Russo ”) for an initial consulting project for up to ...

Detailed price information for Nurexone Biologic Inc (NRX-X) from The Globe and Mail including charting and trades.

SHENZHEN, China, Sept. 16, 2025 /PRNewswire/ -- Kexing Biopharm announced that its investigational Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes has successfully completed a Type II Drug ...

The latest announcement is out from NurExone Biologic ( (TSE:NRX) ).

SUZHOU, China, Sept. 9, 2025 /PRNewswire/ -- ImmVira Group ("ImmVira" or the "Company") recently announced that its lead engineered exosome candidate, MVR-EX105 ("EX105") is featured in a poster ...

Tumor mutation burden (TMB) and Notch1 gene alteration are associated with short disease-free survival in early laryngocarcinoma. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I.